|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||45.08 - 45.31|
|52 Week Range||30.89 - 47.98|
|PE Ratio (TTM)||19.18|
|Dividend & Yield||0.95 (2.10%)|
|1y Target Est||N/A|
The Zacks Analyst Blog Highlights: Pfizer, TJX Companies, Honda, American Electric and Novo Nordisk
The Danish drug maker is the world’s largest manufacturer of insulin. Late yesterday, the company unveiled data from the Sustain-7 trial that shows its diabetes treatment semaglutide bested a competing treatment made by Eli Lilly (LLY) in controlling blood sugar levels and aiding in weight loss. Evercore ISI’s Umer Raffat called it a “best case outcome” for Novo Nordisk.
Novo Nordisk A/S said on Wednesday its diabetes drug met the main goal of reducing glucose levels in patients in a key late-stage trial, setting the stage for it to become the new standard therapy for type 2 diabetes. The 40-week trial tested two dosages of Novo's once-weekly drug, semaglutide, in addition to initial standard-of-care therapy metformin, against Eli Lilly and Co's dulaglutide plus metformin. Novo Nordisk said semaglutide was statistically significant in reducing glucose levels and body weight in about 1,200 patients suffering with type 2 diabetes, when compared with dulaglutide.